

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representation of  
The original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**


**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61B 5/02</b>	<b>A1</b>	(11) International Publication Number: <b>WO 99/12468</b> (43) International Publication Date: 18 March 1999 (18.03.99)
(21) International Application Number: PCT/US97/15807 (22) International Filing Date: 8 September 1997 (08.09.97) (71)(72) Applicant and Inventor: KUNIG, Sabine, Vivian [US/US]; R.D. #1, Box 577, Saltsburg, PA 15681 (US). (74) Agent: POFF, Clifford, A.; P.O. Box 1185, Pittsburgh, PA 15219-1185 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.

(54) Title: METHOD AND APPARATUS FOR MEASURING MYOCARDIAL IMPAIRMENT AND DYSFUNCTIONS FROM EFFICIENCY AND PERFORMANCE DIAGRAMMS



## (57) Abstract

A diagnostic and monitoring device is used to diagnose myocardial impairment, dysfunctions, and the state of critical illness. The device has utility to design and monitor therapies for differential treatment of myocardial impairment, dysfunctions, rehabilitation, and conditioning exercises. Ventricular size, pressures, and heart rate are measured (2) to determine efficiency components, cardiac work and myocardial oxygen consumption, the data being displayed (10) in efficiency, and performance diagrams to diagnose myocardial impairment from cardiac efficiency data, dysfunctions from myocardial oxygen consumption data, and the state of critical illness from cardiac work data.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD AND APPARATUS FOR MEASURING MYOCARDIAL  
IMPAIRMENT AND DYSFUNCTIONS FROM EFFICIENCY  
AND PERFORMANCE DIAGRAMS

BACKGROUND OF THE INVENTION

1. Field of the Invention: The present invention relates to a cardiac monitor and, more specifically, to a method and apparatus for diagnosis  
5 of the degree of myocardial impairment, dysfunction, and the state of critical illness of a subject from efficiency and performance diagrams.

2. Description of Prior Art: Present hemodynamic evaluation of a subject includes the  
10 measurement of a plurality of parameters such as cardiac pressure, heart rate, cardiac output, and pulmonary and vascular resistance and a determination whether these parameters fall into an empirically established normal range. Each parameter is  
15 representative of only a specific aspect of the entire cardiocirculatory system. Therefore, hemodynamic measurements fail to provide an over-all assessment of the system due to the absence of the synergy of the measured data. Ambiguous diagnosis may result from  
20 these types of hemodynamic measurements.

Disclosed in U.S. Patent 5,370,122 is a method and an apparatus to establish the synergy of measured parameters in the form of cardiac pressure-size curves. Deviations of instant pressure-size  
25 curves from basal pressure-size curves produce changes in the numerical values of cardiac efficiency,

indicative of myocardial impairment, and in the numerical values of cardiac work, indicative of dysfunctions. Not disclosed in the '122 patent, however, is the synergy of cardiac efficiency, myocardial oxygen consumption and cardiac power into a single reference frame allowing for diagnosis of dysfunctions, myocardial impairments and critical illness.

It is an object of the present invention to provide an efficiency diagram for diagnosing myocardial impairment and facilitating the design of therapies affecting myocardial impairment and for monitoring the efficacy of these therapies.

It is another object of the present invention to determine more specifically pressure efficiency and volume efficiency from the efficiency diagram to differentially design and/or monitor the efficacy of therapies affecting pressure efficiency and volume efficiency for improvement of cardiac efficiency.

It is still another object of the present invention to provide a performance diagram for diagnosing dysfunctions and critical illness to allow the design of therapies affecting dysfunctions and the critical illness and/or the monitoring of these therapies.

#### SUMMARY OF THE PRESENT INVENTION

According to the present invention there is provided a cardiac diagnostic device for diagnosis of

myocardial impairment, dysfunctions, and critical illness. The device provides means for producing and measuring signals representative of ventricular size, pressures, time intervals of heart beat, and heart rate  
5 from a subject, means for processing said signals, means to determine efficiency and performance diagrams from the processed signals, means for determining pressure, volume, and cardiac efficiencies from the efficiency diagram for diagnosing myocardial  
10 impairment, means for determining cardiac work, ventricular energy, and myocardial oxygen consumption for diagnosing dysfunctions and critical illness from the performance diagram, means for standardizing ventricular work and ventricular energy and ventricular  
15 myocardial oxygen consumption with respect to preselected reference values, and means such as audible or visual signals to alert upon the attainment of specific levels of myocardial impairment and dysfunctions or critical illness.

20                   BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be more fully understood in conjunction with the detailed description of the accompanying drawings in which:

FIG. 1 illustrates an efficiency diagram used  
25 to determine cardiac efficiencies and its components volume efficiency and pressure efficiency for diagnosing myocardial impairment;

FIG. 2 illustrates a performance diagram used to determine ventricular energy, its metabolic equivalent of myocardial oxygen consumption, and cardiac work for diagnosing dysfunctions and the state of critical illness;

FIG. 3 shows a block diagram of the apparatus to practice the instant invention;

FIG. 4 illustrates the utility of the present invention to diagnose cardiac efficiency of an exercising subject, to design rehabilitation and exercising programs, and to determine the intensity levels for beneficial exercise; and

FIG. 5 illustrates the utility of the present invention to diagnose myocardial impairment and dysfunction, design and monitoring of therapies, and drug interventions.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

As disclosed in U.S. Patent 5,370,122, cardiac work per one heart beat (W) is given by the equation:

$$W = (EDVI - ESVI) * (SBP - EDP) \quad (1)$$

where:

EDVI is the end-diastolic volume index,  
ESVI is the end-systolic volume index,  
SBP is the systolic blood pressure, and  
EDP is the end-diastolic pressure.

EDVI and ESVI may be expressed as the ratio of end-diastolic volume, EDV/BSA and end-systolic volume



ESV/BSA where BSA is the body surface area. Cardiac efficiency (CF) is given by the ratio of cardiac work (W) and the ventricular energy available for conversion to work (EDVI\*SBP)

$$5 \quad CF = (EDVI-ESVI)/EDVI * (SBP-EDP)/SBP \quad (2)$$

which may be rewritten as

$$CF = EF(V) * EF(P) \quad (3)$$

where  $EF(V) = (EDVI-ESVI)/EDVI$  is the volume efficiency and  $EF(P) = (SBP-EDP)/SBP$  is the pressure efficiency.

10 Cardiac work expended during the time of one heart beat is given by the ratio of W and the time required for one beat (RR). Similarly, cardiac work per minute (CP) is given by the product of W and heart rate (HR).

$$15 \quad CP = W*HR \quad (4)$$

Combining equations (1), (2), and (4) yields

$$CP = CF * EDVI*SBP*HR \quad (5)$$

which indicates that a fraction (CF) of the available ventricular energy per minute,  $EDVI*SBP*HR$ , is

20 converted to expend CP. It is noted that 1 liter of oxygen is consumed for the liberation of 4.82 kcal of energy. This relation allows conversion of  $EDVI*SBP*HR$  into myocardial oxygen consumption ( $MVO_2$ ) and, accordingly,

$$25 \quad CP = CF * MVO_2 \quad (6)$$

subject to a conversion factor.

Inserting data published for normals at rest in Ciba-Geigy Scientific Tables, Ciba-Geigy

Corporation, Medical Education Division, West Caldwell, NJ 07006, ISBN 0-914168-54-1, 1990 yields basal values, for example, for the right heart  $EF(V) = 60\%$ ,  $EF(P) = 50\%$ ,  $CF = 30\%$ , and  $CP = 0.71 \times 10^6 \text{ erg/m}^2 \cdot \text{sec}$  and for the  
5 left heart  $EF(V) = 63\%$ ,  $EF(P) = 93\%$ ,  $CF = 60\%$  and  $CP = 6.38 \times 10^6 \text{ erg/m}^2 \cdot \text{sec}$ . These basal CP values are used as standards for right and left ventricle (heart), respectively, and assigned a unit of 1 CMET/sec. As a corollary, life cannot be sustained if the basal CP is  
10 not expended. A patient becomes critically ill if  $CP < 1 \text{ CMET/sec}$ . All present readings for a subject are presented as a multiple of 1 CMET/sec.

Inserting the basal values  $CF = 30\%$  and  $CP = 1 \text{ CMET/sec}$  for the right heart into equation 6 yields  
15  $RMVO_2 = 3.33 \text{ CMET/sec}$  which is the basal myocardial oxygen consumption of the right ventricle. Upon the occurrence of a dysfunction, CP expenditure increases to compensate said dysfunction, which, according to equation (6), requires  $MVO_2$  to increase. As a  
20 corollary,  $MVO_2$  greater than the basal value of 3.33 CMET/sec diagnoses a dysfunction.

Referring now to FIG. 1, in an efficiency diagram volume efficiency is plotted versus pressure efficiency. Curves are added to interconnect points in  
25 the efficiency diagram having equal values of the product  $EF(V)$  and  $EF(P)$  or equal values of  $CF$ , according to equation (3). Further, basal values of volume and pressure efficiency are added to the

efficiency diagram as horizontal and vertical lines. The bold CF curve in FIG. 1 indicates basal cardiac efficiency, for example, for the right ventricle, for which  $CF = 30\%$ . A myocardial impairment exists if CF does not attain values as indicated by the basal CF curve. As will be apparent to those skilled in the art, the cardiac efficiency diagram for the left heart will have a basal cardiac efficiency, for example, of  $CF=60\%$  and a plurality of similar curves for the left heart having different values for efficiency and myocardial oxygen consumption may be shown in a similar manner for that displayed in the right heart in FIG. 1. The efficiency diagram curves can be produced either as a function of the computer program or as a transparent overlay on the monitor.

Referring now to FIG. 2, in a performance diagram CF is plotted versus  $EDVI \cdot SBP \cdot HR$  or, alternatively, versus  $MVO_2$ . Curves are added to interconnect points in the performance diagram having equal values of CP. Further, basal values for CF and  $MVO_2$  are added as horizontal and vertical lines. A myocardial impairment exists below the horizontal line, a dysfunction exists to the right of the vertical line, and a patient is critically ill in the zone defined by the  $CP = 1$  CMET/sec curve and the  $CP = 0.5$  CMET/sec curve. The patient is near death when approaching the  $CP = 0.5$  CMET/sec curve. The curves of the performance diagram can be produced either as a function of the

computer program or as a transparent overlay on the monitor.

The embodiment, as shown in FIG. 3 illustrates the teachings of the instant invention.

5 Accordingly, sensors 2 are placed on a subject 1 to detect signals representative of end-diastolic volume, end-systolic volume, systolic blood pressure, end-diastolic blood pressure, time for one heart cycle, and heart rate which are transmitted on multi-line wire 3  
10 to computer 4. Such sensors 2 may include catheters, ultra-sound equipment, and pressure transducers as required for differential assessment of the left or right heart. Additional input representative of patient information including weight, height, body  
15 surface area, and preselected basal values is provided from a keyboard 5 to computer 4 on line 6. Computer 4 is programmed to process all incoming signals for determination of volume efficiency, pressure efficiency, cardiac efficiency, cardiac work,  
20 ventricular energy, and ventricular myocardial oxygen consumption, said parameters being transmitted by line 8 to a monitor 9 which is comprised of a display 10, audible and visual alarms 11 to warn of emergencies if preset values of the parameters are attained, and  
25 indicators 12 to diagnose myocardial impairment, dysfunction, and critical illness from the attainment of specific values of cardiac efficiency, myocardial oxygen consumption, and cardiac work. Inputs from

keyboard 5 may be used to select from among the various diagrams for display by display 10 along with plotted points representing instant conditions of a monitored subject. The signal displayed by display 10 and the audio and visual alarms 11 and the signals displayed by indicator 12 are transmitted on line 14 to a printer 13 for producing hard copies and on line 16 to a modem 15 for transmission over telephone lines to central storage. A memory 17 in the computer 4 serves as storage of all information and data.

Referring now to FIGS. 1 and 2 collectively, data shown in Table 1, as published by J. W. Biondi, et al. in an article entitled The Effect of Incremental Positive End-Expiratory Pressure on Right Ventricular Hemodynamics and Ejection Fraction, Anesthesia Analgesia 1988; 67:144-151, on patients with acute respiratory disease are used to demonstrate the utility of efficiency and performance diagrams to diagnose myocardial impairment, dysfunction, and critical illness from right ventricular data.

Table 1

PEEP			0 cm H <sub>2</sub> O	5 cm H <sub>2</sub> O	10 cm H <sub>2</sub> O	20 cm H <sub>2</sub> O
			▽	▼	□	■
=====						
25	SBP	mm Hg	39	43	44	48
	EDP	mm Hg	6	7	6	8
	EDVI	ml/m <sup>2</sup>	103	92	95	113
	ESVI	ml/m <sup>2</sup>	60	48	55	79

		10			
HR	1/min	101	102	103	103
EF(V)	%	42	48	42	30
EF(P)	%	79	84	77	75
5 CF	%	33	40	32	23
MVO <sub>2</sub>	CMET/sec	12.7	12.6	13.5	17.6
CP	CMET/sec	4.2	5.1	4.4	3.9

These patients were treated with positive end-expiratory pressures (PEEP) of varying magnitudes indicated by the symbols ▽ no PEEP, ▽ 5 cm H<sub>2</sub>O PEEP, □ 10 cm H<sub>2</sub>O PEEP, and ■ 20 cm H<sub>2</sub>O PEEP. The computer 4 receives input signals representative of EDVI, ESVI, SBP, EDP, and HR, processes them to determine EF(V), EF(P), CF, RMVO<sub>2</sub>, and CP. Subsequently, computer 4 15 generates a performance and an efficiency diagram. According to the teachings of the instant invention, the cardiac monitor of FIG. 3 by displaying a performance diagram of FIG. 1 reveals a dysfunction (in this case a respiratory disease) as RMVO<sub>2</sub> significantly 20 exceeds the basal RMVO<sub>2</sub>. No myocardial impairment is revealed by the cardiac monitor for no PEEP treatment and for PEEP treatments not exceeding 10 cm H<sub>2</sub>O since cardiac efficiencies for the respective treatments exceed the basal cardiac efficiency below which 25 impairment is indicated. Still further, the cardiac monitor reveals a PEEP of 5 cm H<sub>2</sub>O as the most beneficial pressure to elevate cardiac efficiency to its highest levels.

In another aspect of the teachings of the present invention the cardiac device of FIG. 3 by displaying an efficiency diagram of FIG. 1, containing a data point representing an instant condition of a monitored subject, reveals depressed volume efficiencies which are compensated by elevated pressure efficiencies to result in an over-all normal cardiac efficiency for no PEEP treatment and PEEP treatments not exceeding 10 cm H<sub>2</sub>O. The cardiac monitor also detects a concomitant volume efficiency and pressure efficiency deterioration for PEEP of 20 cm H<sub>2</sub>O resulting in an abnormally low cardiac efficiency representative of myocardial impairment. The cardiac monitor, thus, allows the design of specific therapies affecting myocardial impairment through volume efficiency and pressure efficiency, and design of therapies affecting dysfunctions and the monitoring of these therapies.

In still another embodiment of the present invention representations of CF in form of  $EF(V)$ ,  $EF(P)$ , and  $EF(A) = (EDAI - ESAI) / EDAI$  and representations of  $MVO_2$  in form of  $EDVI \cdot HR$ ,  $SBPI \cdot HR$ , where  $SBPI$  equals the ratio of pressure to body surface area,  $EDAI \cdot SBP \cdot HR$ , where  $EDAI$  equals the end-diastolic cross-sectional area referenced to BSA of the ventricle end  $ESAI =$  the end-systolic cross-sectional area referenced to BSA may be used, respectively, for the left heart and the right heart, as well as the substitution of

ventricular pressures by arterial pressures, right  
 ventricular pressure by pulmonary artery pressure or  
 central venous pressure, left ventricular systolic  
 pressure by arterial systolic and left ventricular  
 5 diastolic pressure by wedge pressure or arterial  
 diastolic pressure to determine efficiency and  
 performance diagrams for right and left ventricles.

Referring now to Table 2, there are listed  
 heart rate and blood pressure data as published by R.  
 10 A. Wolthuis et. al. in an article entitled, The  
response of healthy men to treadmill exercise,  
 Circulation 1977;55:153-157, which were used to  
 determine left ventricular myocardial oxygen  
 consumption and pressure efficiency to practice the  
 15 instant invention to design and monitor rehabilitation  
 and conditioning exercise programs.

Table 2

Age				26 years	47 years
=====					
20	BSA	[m <sup>2</sup> ]	rest	1.77	2.13
	SBP	[mm Hg]	rest	115	140
	SBP(1)	[mm Hg]	sub-maximal	132	174
	SBP(2)	[mm Hg]	sub-maximal	148	193
	SBP(3)	[mm Hg]	sub-maximal	160	208
25	SBP	[mm Hg]	maximal	164	216
	EDP	[mm Hg]	rest	80	90
	EDP(1)	[mm Hg]	sub-maximal	68	90
	EDP(2)	[mm Hg]	sub-maximal	65	90



13

	EDP(3)	[mm Hg]	sub-maximal	60	90
	EDP	[mm Hg]	maximal	60	96
	HR	[1/min]	rest	60	82
	HR(1)	[1/min]	sub-maximal	102	141
5	HR(2)	[1/min]	sub-maximal	130	174
	HR(3)	[1/min]	sub-maximal	158	190
	HR	[1/min]	maximal	200	188
<hr/>					
	EF(P)	[%]	rest	30	36
10	EF(P)(1)	[%]	sub-maximal	48	48
	EF(P)(2)	[%]	sub-maximal	56	53
	EF(P)(3)	[%]	sub-maximal	63	57
	EF(P)	[%]	maximal	63	56
	MVO <sub>2</sub>	[CMET/sec]	rest	3.33	4.43
15	MVO <sub>2</sub> (1)	[CMET/sec]	sub-maximal	6.25	9.46
	MVO <sub>2</sub> (2)	[CMET/sec]	sub-maximal	8.93	13.0
	MVO <sub>2</sub> (3)	[CMET/sec]	sub-maximal	11.73	15.2
	MVO <sub>2</sub>	[CMET/sec]	maximal	13.3	15.7
	CP	[CMET/sec]	rest	1.0	1.59
20	CP	[CMET/sec]	sub-maximal	3.0	4.54
	CP	[CMET/sec]	sub-maximal	5.0	6.89
	CP	[CMET/sec]	sub-maximal	7.39	8.66
	CP	[CMET/sec]	maximal	8.38	8.79

Referring now to the performance diagram

25 shown in FIG. 4, there is plotted pressure efficiency as a representation of cardiac efficiency and SBPI\*HR

as a representation of  $MVO_2$  for the left heart for two groups of subjects of different ages exercising on a treadmill. The symbols denote time on the treadmill as follows v at rest prior to commencement of the treadmill test, v stage 1, sub-maximal response, □ stage 2 sub-maximal response, ■ stage 3 sub-maximal response, Δ maximal response. Subjects of the younger age group utilize a smaller amount of oxygen more efficiently as compared to the subject of older age. A threshold efficiency is attained prior to maximal exertion. Thus, the cardiac monitor of FIG. 3 allows the design of exercise programs, for example, for cardiac rehabilitation and for competitive athletes at the threshold of maximum efficiency to assure safety of cardiac patients and progress in the conditioning program of athletes.

Referring now to Table 3, there are listed heart rate and blood pressure data as published by A. S. Phillips et. al. in an article entitled Propofol-Fentanyl anesthesia: A comparison with Isoflurane-Fentanyl anesthesia in coronary artery bypass grafting and valve replacement surgery, Journal of Cardiothoracic and Vascular Anesthesia 1994;8:289-296, which were used to determine left ventricular myocardial oxygen consumption and pressure efficiency to practice the instant invention to design and monitor drug therapies such as anesthesia.

Table 3

15

pre-anesthesia post-anesthesia

=====			
	BSA [m <sub>2</sub> ]	1.91	1.91
	HR [1/min]	61	65
5	SBP [mm Hg]	127	105
	EDP [mm Hg]	66	60
<hr/>			
	EF(P) [%]	48	43
	MVO <sub>2</sub> [CMET/sec]	3.33	2.94
10	CP [CMET/sec]	1.6	1.26

Referring now to FIG. 5, there is shown the performance diagram, created by the monitor of FIG. 3 which uses data from Table 3, of a group of patients in whom anesthesia is administered, where  $\nabla$  denotes the state prior to anesthesia and  $\nabla$  the state after anesthesia administration by the drug Propofol-Fentanyl. The patient shows a decreased cardiac efficiency representative of myocardial impairment caused by the anesthesia. Thus, the cardiac monitor has utility to design therapies and monitor efficacy of therapies, drug interventions and the safety of patients.

In yet another embodiment numerous values for each of CF, MVO<sub>2</sub>, CP and their representations may be collected and displayed in time reference frames including the time derivatives to further monitor progress or regress of myocardial impairments and dysfunctions.

While the present invention has been described in connection with the preferred embodiments of the various figures, it is to be understood that other similar embodiments may be used or modifications and additions may be made to the described embodiment for performing the same function of the present invention without deviating therefrom. Therefore, the present invention should not be limited to any single embodiment, but rather construed in breadth and scope in accordance with the recitation of the appended claims.

CLAIMS

I claim:

1. A cardiac diagnostic device for monitoring a subject, said device including:

means for measuring physiological parameters of such subject;

5 means responsive to measurements of physiological parameters of such subject for deriving values of cardiac efficiency and myocardial oxygen consumption;

means for establishing a boundary of physiological criticality in a first reference frame of  
10 cardiac efficiency versus myocardial oxygen consumption; and

means using said cardiac efficiency and myocardial oxygen consumption of such subject for  
15 establishing a subject data point in said first reference frame whereby a comparison is allowed between said subject data point and said boundary of physiological criticality.

2. The cardiac diagnostic device according to claim 1 wherein said boundary of physiological criticality includes at least one curve in said first reference frame, said curve containing at least one reference point representing an absence of dysfunction and myocardial impairment.

3. The cardiac diagnostic device according to claim 2 wherein said means responsive to said

measurements further derives cardiac pressure efficiency and cardiac volume efficiency for such  
5 subject;

and wherein said means for establishing a boundary of physiological criticality further establishes at least one cardiac efficiency curve in a cardiac efficiency reference frame of cardiac volume  
10 efficiency versus cardiac pressure efficiency, said cardiac efficiency curve containing a basal reference point representing a basal value for cardiac volume efficiency and a basal value for cardiac pressure efficiency;

15 and wherein said means for establishing a subject data point in said first reference frame further establishes a second subject data point in said cardiac efficiency reference frame using said derived cardiac pressure efficiency and cardiac volume  
20 efficiency whereby a comparison is allowed between said second subject data point and said cardiac efficiency curve for the left or right heart.

4. The cardiac diagnostic device according to claim 2 wherein said means for establishing a boundary includes a second curve establishing a zone of physiological criticality with said at least one curve at which death is imminent.

5. The cardiac diagnostic device according to claim 2 wherein said at least one curve further establishes a basal level of cardiac work expended, and

wherein said means for establishing further provides a plurality of curves representing elevated levels of cardiac work expended relative to said basal level.

6. The cardiac diagnostic device according to claim 3 wherein said cardiac efficiency curve consists of a plurality of cardiac efficiency curves in said cardiac efficiency reference frame.

7. The cardiac diagnostic device according to claim 3 wherein said cardiac efficiency is defined as the product of cardiac volume efficiency and cardiac pressure efficiency.

8. The cardiac diagnostic device according to claim 3 wherein said cardiac efficiency curve represents a cardiac basal efficiency value for all values of cardiac volume efficiency and cardiac pressure efficiency.

9. The cardiac diagnostic device according to claim 1 wherein said measurements of physiological parameters include signals representative of ventricular size, ventricular blood pressure, time for completion of one cardiac cycle, and heart rate.

10. The cardiac diagnostic device according to claim 1 wherein said means responsive to physiological measurements of physiological parameters further derives volume efficiency, pressure efficiency, cardiac work and available energy for conversion to cardiac work.

11. The cardiac diagnostic device according to claim 3 further including using said subject data point and said curve in said first reference frame and second subject data point and said cardiac efficiency curve in said cardiac efficiency frame to design and monitor therapies for differential treatment of myocardial impairment or dysfunction.

12. The cardiac diagnostic device according to claim 3 further including using said subject data point and said curve in said first reference frame and second subject data point and said cardiac efficiency curve in said cardiac efficiency frame to design and monitor exercise programs for cardiac rehabilitation and conditioning of subjects.

13. A method of diagnosing myocardial impairments, dysfunctions and physiological criticality of a subject, said diagnostic method including the steps of:

5 monitoring such subject to obtain measurements representative of physiological parameters;

determining cardiac efficiency and myocardial oxygen consumption for such subject using said representative measurements;

10 establishing a boundary of physiological criticality in a first reference frame of cardiac efficiency versus myocardial oxygen consumption;



21

establishing a subject data point in said  
15 first reference frame which represents said determined  
cardiac efficiency and myocardial oxygen consumption  
for such subject; and

comparing said subject data point with said  
boundary to indicate physiological criticality.

14. The method according to claim 13  
including the further steps of:

providing at least one curve in said first  
reference frame containing at least one reference point  
5 which represents an absence of dysfunction and  
myocardial impairment; and

comparing said subject data point to said at  
least one curve to diagnose myocardial impairments and  
dysfunctions of the left or right heart of such subject  
using said reference point of said curve.

15. The method according to claim 14,  
wherein said diagnosis of impairment is made by  
comparing the position of said data point with said  
reference point with respect to said cardiac efficiency  
5 of said first reference frame, and wherein said  
diagnosis of dysfunction is made by comparing the  
position of said data point with said reference point  
with respect to said myocardial oxygen consumption of  
said first reference frame.

10 16. The method according to claim 14,  
including the further steps of:

determining cardiac pressure efficiency and cardiac volume efficiency for such subject using said representative measurements;

15 providing at least one cardiac efficiency curve in a cardiac efficiency reference frame of cardiac volume efficiency versus cardiac pressure efficiency, said cardiac efficiency curve containing an  
20 basal reference point representing a basal value for cardiac volume efficiency and a basal value for cardiac pressure efficiency;

25 establishing a second subject data point in said cardiac efficiency reference frame using said determined cardiac pressure efficiency and cardiac volume efficiency;

comparing said second subject data point with said cardiac efficiency curve to determine more specifically a cardiac condition and to aid in designing therapies affecting said impairments and dysfunctions.

5 17. The method according to claim 16 wherein said comparison of said second subject data point with said cardiac efficiency curve involves comparing the volume efficiency of said second subject data point with the basal volume efficiency and comparing the pressure efficiency of said second subject data point with the basal pressure efficiency.

18. The method according to claim 16 further including the step of designing and monitoring

therapies, exercise and rehabilitation programs in response to said step of comparing.

19. The cardiac diagnostic device according to claim 10, wherein said means for establishing further provides a plurality of progression curves each in one progress reference frame, each of said progression reference frames having one of said derived values versus time, said progression curves containing points representing instant values of said derived values or their time derivatives for such subject at different times during a therapy treatment or an exercise program.

5

# Efficiency Diagram




Fig. 1

# Performance Diagram




Fig. 2

3/5




Fig. 3

# Performance Diagram




Fig. 4

# Performance Diagram




Fig. 5



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/15807**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : A61B 5/02

US CL : 128/668

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 128/668, 672, 700

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,370,122 A (KUNIG et al) 06 December 1994, entire document.	1-19
A	US 5,584,298 A (KABAL) 17 December 1996, entire document.	1-19

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

20 OCTOBER 1997

Date of mailing of the international search report

07 NOV 1997

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

GEORGE EVANISKO

Telephone No. (703) 308-2612

Form PCT/ISA/210 (second sheet)(July 1992)\*

**THIS PAGE BLANK (USPTO)**